

PC25581A  
Response to Office Action For Appln. No 10/816,242

Certificate of Transmission (37 C.F.R. §1.8);  
I hereby certify that this correspondence is being  
electronically transmitted via **EFS-Web** to the United  
States Patent and Trademark Office, **Petitions** on this  
17th day of **March** 2008.

s/ /Donna Di Maccio/  
**Donna Di Maccio**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re the Application of:  
**James Freddo et al.**

Group Art Unit: **1614**

Serial No.: **10/816,242**

Examiner: **Shirley V. Gembeh**

Confirmation No.: **9207**

Filed: **April 1, 2004**

For: **DOSAGE FORMS AND METHODS OF  
TREATMENT USING VEGFR INHIBITORS**

Sir:

**PETITION FOR EXTENSION OF TIME PURSUANT TO 37 C.F.R. § 1.136(a)**

Pursuant to the provisions of 37 C.F.R. § 1.136(a), it is requested that the term for response to the Office Action mailed October 18, 2007 in this patent application be extended by two months, so that the expiration for the Office Action response is extended to March 18, 2008.

Authorization is hereby provided to charge the extension fee as provided under 37 C.F.R. § 1.17, as well as any additional fees required, or to credit any overpayment, to Deposit Account 16-1445.

Respectfully submitted,

Date: March 17, 2008

/Elsa Djuardi Lemoine/  
Elsa Djuardi Lemoine  
Attorney for Applicants  
Reg. No. 45,963

Pfizer, Inc.  
Patent Dept.  
10555 Science Center Drive  
San Diego, CA 92121  
(858) 638-6117  
(858) 678-8233 (fax)